Investors

Corporate Fact Sheet

MPM Capital
Sofinnova Ventures
Alloy Ventures
GBS Venture Partners
Mitsubishi UFJ Capital
Genzyme Ventures
Baxter International, Inc.
Development Bank of Japan
5AM Ventures
Bio*One Capital Pte. Ltd.

Financial Conference Presentations

Washington, DC – June 2011
2011 BIO International Convention Business Forum

New York, NY – April 2011
10^th Annual Needham Healthcare Conference

New York, NY – November 2010
Lazard Capital Markets 7^th Annual Healthcare Conference

KaloBios Investor Contact:

IR@kalobios.com

Recent Corporate Highlights

A Phase 1 clinical trial was initiated for KB004.
KaloBios partnered with Sanofi Pasteur for KB001A in hospital indications.
Two Phase 1/2 trials for KB001 (anti-Pseudomonas antibody) were completed; one in cystic fibrosis and another in intensive care patients on mechanical ventilation.
A multi-dose safety trial was completed for KB003.
Three Phase 1/2 trials for KB002 (a prototype anti-GM-CSF antibody) were completed, including trials in asthma and rheumatoid arthritis.